PubMed Health⌕ Search

PubMed · 3373113

Multimodality evoked potentials in sarcoidosis.

Abstract

Neurosarcoidosis is suspected on clinical grounds and then confirmed by radiography, by spinal fluid examination, or by biopsy. To determine whether evoked potential testing may also be of value in diagnosing and following the course of neurosarcoidosis, multimodality evoked potentials were obtained in 12 men with sarcoidosis, including two with neurosarcoidosis. Seven of 12 subjects, one of whom had neurosarcoidosis, manifested abnormal evoked potentials. Visual evoked potentials were abnormal in one patient and somatosensory evoked potentials were abnormal in one patient. Five additional patients, including one with neurosarcoidosis, had abnormal auditory evoked potentials suggestive of auditory nerve or low pons involvement. These data indicate that multimodality evoked potentials, especially auditory potentials, may show central nervous system involvement in patients with sarcoidosis in the absence of clinically apparent disease.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N P Verma, S G Desai, M R Simon, S D King. 1988. Multimodality evoked potentials in sarcoidosis.. https://pubmed.ncbi.nlm.nih.gov/3373113/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗